## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.	.C. 20549
----------------	-----------

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Abdun-Nabi Daniel					2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ]									k all app	olicable)	g Person(s) to	ssuer Owner	
(Last) 400 PRO	Last) (First) (Middle) 00 PROFESSIONAL DR, SUITE 400						3. Date of Earliest Transaction (Month/Day/Year) 05/20/2016									er (give title w) Presider	Other below of & CEO	(specify /)
(Street) GAITHERSBURG MD 20879 (City) (State) (Zip)				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Ind Line)	ividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
		Tabl	e I - Nor	-Deriv	ative	Sec	uritie	s Ac	quired,	Dis	posed o	f, or E	Benef	ficially	Own	ed		
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)				Execution Date,		Transaction Dispo						Securi Benefi	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) (D)	or I	Price	Transa	action(s) 3 and 4)		(111501.4)
Common Stock <sup>(1)(2)</sup> 05/20/					/2016			S		8,701	. ]	D	\$42 <sup>(3)</sup>	179,665		D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date or Exercise (Month/Day/Year) if any		Date, Transaction Code (Instr					6. Date E Expiratio (Month/D	•	7. Title Amour Securi Underl Deriva Securi and 4)	nt of ties ying tive	Dei Sec (Ins	Price of ivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	or Numb of Share					

## **Explanation of Responses:**

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
- 2. Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended.
- 3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$41.82 to \$42.22, inclusive.

/s/ Eric Burt, Attorney-in-fact 05/24/2016

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.